A growing body of literature suggests that regular physical exercise may improve cognitive function in people with MS. However, a specific regimen for this has yet to be determined. While no diet has been shown to affect cognition in people with MS per se , a heart-healthy diet may reduce the risk of comorbidities other diseases that can contribute to cognitive impairment.
The diet should also limit saturated fats and refined sugars. Following this type of eating plan may limit comorbidities such as vascular disease, type 2 diabetes, or high blood pressure.
All of these conditions can contribute to cognitive impairment and disability in people with MS. Smoking is a risk factor for brain atrophy, so quitting smoking may help to limit further atrophy.
Barbara S. Giesser has conducted peer-reviewed research into the effects of exercise in persons with MS. Multiple sclerosis MS can cause cognitive changes. Managing these changes effectively may help slow them down and reduce their effect on your life.
Multiple sclerosis MS can cause immediate symptoms or longer-term issues that arise slowly over time. Managing both types of issues may improve your….
Unhappy with your RRMS medication? Also learn about side effects, other safety considerations…. Health Conditions Discover Plan Connect. Written by Barbara S. People with MS typically experience one of four disease courses types of MS. There are over a dozen treatments to help modify the MS disease process. Here are a few related topics that may interest you. You're already registered - Thanks! Sign in here to manage your preferences. What is your connection to MS?
The range of symptoms is different for each person with MS. Once the inflammation caused by the immune attack is over, it is possible for the body to replace damaged myelin. This process is known as remyelination. Although the new myelin can work effectively, it tends to be thinner than unaffected myelin and so messages through the affected nerves may not be as fast as before the attack.
Remyelination tends to occur in the earlier stages of MS but, with repeated relapses or attacks, oligodendrocytes become damaged and destroyed. Eventually, they may not be able to produce more myelin. If an axon is left without the protection of myelin it will be more vulnerable to damage and may die. Your central nervous system is able to overcome small areas of nerve damage by rerouting messages using undamaged nerve cells.
This ability to adapt to avoid damaged areas is called plasticity. Messages may take longer to get through but your symptoms will improve to some extent. Should the area of damage become too large, this rerouting process is no longer able to compensate. Messages to or from that part of the central nervous system are permanently blocked, resulting in symptoms that do not improve for you. Remyelination and neuroprotection are potential areas where new treatments could be developed.
Some research is looking into drugs that protect nerves from damage and so halt or slow down the progression of MS.
Some research is investigating drugs that promote myelin repair, which would mean that damage could be reversed and function improved. Find out how your support helps make a difference. With your help, we can change the life of every person affected by multiple sclerosis. Glial cells make up to half of brain volume, supporting and protecting the nerve cells. Research shows they matter in multiple sclerosis. Find out more in this A-Z entry.
Dahms, K. Matzel, and J. View at: Google Scholar F. Khan, J. Pallant, J. Pallant, C. Brand, and T. Miller , C. Simpson, and W. View at: Google Scholar H. Lilius, E. Valtonen, and J. View at: Google Scholar J. Minderhoud, J. Leemhuis, and J. Zorzon, R. Zivadinov, A.
Bosco et al. View at: Google Scholar K. Beier, D. Goecker, S. Babinsky, and C. View at: Google Scholar D. Mattson, M. Petrie, D. Srivastava, and M. Betts, S. Jones, C. Fowler, and C. Borello-France, W. Leng, M. O'Leary et al. Gruenwald, Y. Vardi, I. Gartman et al. Yetimalar, M. Gedizlioglu et al. Fowler, J. Miller, and M.
Hinds, B. Eidelman, and A. View at: Google Scholar Y. Chia, C. Fowler, M. Kamm, M. Henry, M. Lemieux, and M. Chia, K. Gill, J. Jameson et al.
Weber, P. Grise, and M. View at: Google Scholar W. Jost, B. Schrank, A. Herold, and O. Sterman, P. Coyle, D. Panasci, and R. View at: Google Scholar A. McDougall and J. Merkelbach, U. Dillmann, C. Holz, and M. Stojkovic, J. Gauvrit et al. Flachenecker, K.
Reiners, M. Krauser, A. Wolf, and K. Nazliel, C.
0コメント